- Title
- Clinical implications of lncRNA LINC-PINT in cancer
- Creator
- Bukhari, Ihtisham; Khan, Muhammad Riaz; Li, Fazhan; Swiatczak, Bartlomiej; Thorne, Rick Francis; Zheng, Pengyuan; Mi, Yang
- Relation
- Frontiers in Molecular Biosciences Vol. 10, no. 1097694
- Publisher Link
- http://dx.doi.org/10.3389/fmolb.2023.1097694
- Publisher
- Frontiers Research Foundation
- Resource Type
- journal article
- Date
- 2023
- Description
- Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.
- Subject
- PINTology; LncRNA; LINC-PINT; colon adenocarcinoma (CAC); cancer biomarkers; cancer therapy
- Identifier
- http://hdl.handle.net/1959.13/1485479
- Identifier
- uon:51603
- Identifier
- ISSN:2296-889X
- Language
- eng
- Reviewed
- Hits: 1151
- Visitors: 1147
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|